FDA Warns Foreign Personal-Care Firms For Monograph, GMP Violations
This article was originally published in The Rose Sheet
Executive Summary
An August letter to Jabones Pardo is the latest in a string of FDA warnings to international firms that market personal-care products for acne treatment, pain relief and other indications in violation of U.S. drug regulations. Warnings to OTC product firms outside the U.S. over the past two years reflect the higher priority FDA has assigned to inspecting international firms.
You may also be interested in...
FDA Shutdown Lands Hard On CFSAN-Regulated Industries
The federal shutdown interrupts CFSAN’s increasing enforcement against firms marketing violative products, in addition to putting routine facility inspections on hold. FDA retains 8,180 staff members, about 55% of its total, mostly because they could be “paid from carryover funding.”
Most U.S. Sunscreens Not So Hot, Reflecting FDA Failures – EWG
The majority of sunscreen products in the U.S. still don’t meet the Environmental Working Group’s standards. Just 25% of the sunscreen products evaluated for the group’s 2013 Sunscreen Guide pass muster, underscoring the need for a finalized sunscreen monograph and ingredient options for sunscreen formulators on par with those in Europe, EWG says.
FDA Enforcement Priorities: Eye Products, Dual Drug/Cosmetic Firms
When FDA inspects a facility producing both drugs and cosmetics, the manufacturer should be using one standard and that’s the drug standard, says Karyn Campbell, director of the investigations branch at FDA’s Philadelphia District Office.